Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Zhejiang Kanglaite to Start US Phase III Trial of TCM Cancer Drug

publication date: Jun 29, 2015
Zhejiang Kanglaite Group will start a large US Phase III trial of its lead drug, Kanglaite, a TCM-derived medication, in patients with pancreatic cancer. The company says Kanglaite Injection is a novel dual-function drug that kills cancer cells while strengthening immune function. Its active ingredient is derived from coix, a grass related to rice and maize. The trial of the drug, which has been approved in China since 1995, will be conducted by Kanglaite's US subsidiary.

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital